Dr Ronald Kent De Venecia, MD, PHD | |
243 Charles St, Boston, MA 02114-3002 | |
(617) 573-3715 | |
Not Available |
Full Name | Dr Ronald Kent De Venecia |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Experience | 27 Years |
Location | 243 Charles St, Boston, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1700865375 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207YX0901X | Otolaryngology - Otology & Neurotology | 226406 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Massachusetts Eye And Ear Infirmary - | Boston, MA | Hospital |
Massachusetts General Hospital | Boston, MA | Hospital |
Brigham And Women's Hospital | Boston, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Massachusetts Eye And Ear Associates, Inc | 4486540275 | 337 |
News Archive
Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for CepleneĀ® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
Sooner or later, most cancer patients develop resistance to the very chemotherapy drugs designed to kill their cancer, forcing oncologists to seek alternatives.
Men do not engage in riskier behaviors after they are circumcised, according to a study in Kenya by University of Illinois at Chicago researchers.
› Verified 5 days ago
Entity Name | Massachusetts Eye And Ear Associates, Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1932574332 PECOS PAC ID: 4486540275 Enrollment ID: O20040227000123 |
News Archive
Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for CepleneĀ® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
Sooner or later, most cancer patients develop resistance to the very chemotherapy drugs designed to kill their cancer, forcing oncologists to seek alternatives.
Men do not engage in riskier behaviors after they are circumcised, according to a study in Kenya by University of Illinois at Chicago researchers.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Ronald Kent De Venecia, MD, PHD 243 Charles St, Boston, MA 02114-3002 Ph: (617) 573-3715 | Dr Ronald Kent De Venecia, MD, PHD 243 Charles St, Boston, MA 02114-3002 Ph: (617) 573-3715 |
News Archive
Pulmonary artery denervation is feasible and may reduce pulmonary arterial pressure in patients with pulmonary arterial hypertension, phase II findings suggest.
EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for CepleneĀ® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.
Sooner or later, most cancer patients develop resistance to the very chemotherapy drugs designed to kill their cancer, forcing oncologists to seek alternatives.
Men do not engage in riskier behaviors after they are circumcised, according to a study in Kenya by University of Illinois at Chicago researchers.
› Verified 5 days ago
Dr. Steven D. Rauch, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-523-7900 | |
Elliott D. Kozin, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-6545 | |
Katherine Nicole Vandenberg, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 830 Harrison Ave Ste 1400, Boston, MA 02118 Phone: 617-638-8124 | |
Yoon Sun Chun, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Brigham And Women's Hospital Dept Of Plastic Surgery, Boston, MA 02115 Phone: 617-732-8181 Fax: 617-983-4534 | |
Jaimie Derosa, M.D. Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 91 Newbury St, Suite 300, Boston, MA 02116 Phone: 617-262-8000 Fax: 617-262-8002 | |
Dr. Usama M Aboelkheir, MD Otolaryngology Medicare: Medicare Enrolled Practice Location: 736 Cambridge St, Smc8, Boston, MA 02135 Phone: 617-789-5004 Fax: 617-779-6481 | |
Phillip C Song, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 243 Charles St, Boston, MA 02114 Phone: 617-573-3557 |